In-Silico Identification and Evaluation of Diosgenin as a Promising Phytomedicine Targeting MHC-I for Cancer Therapy
Abstract
Immunotherapeutic
strategies
targeting
MHC-I
have
gained
significant
attention
for
combating
cancer,
a
leading
global
health.
However,
the
emergence
of
therapeutic
resistance
and
manifestation
adverse
concerneffects
associated
with
conventional
treatment
modalities
underscore
imperative
innovative
strategies.
In
current
study,
we
conducted
an
“in
silico” investigation
to
identify
potential
phytomedicines
cancer
(3AM8).
Using
AutodockTools
software,
408
natural
secondary
polyphenols
were
screened
against
MHC-I,
Diosgenin
exhibiting
highest
affinity
binding
(−8.93
Kcal/mol).
Pharmacokinetic
profiling
highest-ranking
ligands
elucidated
their
suitability
subsequent
development
optimization.
Molecular
dynamics
simulations,
using
Desmond
software
suite,
demonstrated
pronounced
stability
Diosgenin-MHC-I
complex
throughout
100-ns
trajectory.
Our
findings
suggest
that
holds
promise
as
candidate
therapeutics;
however,
further
verifications
by
use
extensive
vitro”
vivo”research
is
warranted
substantiate
its
validity
potential.
This
study
highlights
in
upcoming
trial
regimens
advances
choices
treating
cancer.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 26, 2025
Language: Английский